Sign inJoin waitlistJoin the waitlist

Auris Huen

Chief, Section of Cutaneous Lymphoma · University of Texas M D Anderson Cancer Center

Credentials: · · ·

History

Section of Cutaneous Lymphoma Division · University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

Dermatology
Hospital of the University of Pennsylvania
2012–2015
Baylor College of Medicine
2011–2012
McGovern Medical School at The University of Texas Health Science Center at Houston
2007–2011
University of Texas M D Anderson Cancer Center
2000–2001
University of California-San Francisco
1999–2000

Research

Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions
Case report · Journal of Cutaneous Pathology · 2016 · 105 citations
Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a…
The Lancet Oncology · 2025 · 84 citations
Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features
Case report · American Journal of Dermatopathology · 2017 · 83 citations

MD
Madeleine Duvic
20 papers
Carlos Torres-Cabala
16 papers
Swaminathan Iyer
13 papers
Jonathan Curry
12 papers
Phyu Aung
11 papers
PN
Priyadharsini Nagarajan
9 papers · 5 as a resident
Victor Prieto
9 papers
Bouthaina Dabaja
8 papers
Michael Tetzlaff
7 papers
YK
Youn-Hee Kim
7 papers
RM
Roberto Miranda
6 papers
SH
Steven Horwitz
6 papers

Clinical trials

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Principal investigator · Recruiting · Phase 1
SciTech Development, Inc.
2023–2027
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma
Principal investigator · Completed · Phase 1
Rhizen Pharmaceuticals SA
2015–2018
SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)
Principal investigator · Active not recruiting · Phase 2
M.D. Anderson Cancer Center
2011–2028
A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab
Site PI · Recruiting
City of Hope Medical Center
2024–2026